Pharma Mar (OTCMKTS:PHMMF) Upgraded to Hold at Zacks Research

Pharma Mar (OTCMKTS:PHMMF) was upgraded by analysts at Zacks Research to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other analysts also recently weighed in on the company. BTIG Research assumed coverage on Pharma Mar in a research note on Thursday, April 23rd. They set a “buy” rating on the stock. Chardan Capital raised Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy”.

Pharma Mar Price Performance

Shares of OTCMKTS PHMMF opened at $79.49 on Monday. Pharma Mar has a 12-month low of $77.41 and a 12-month high of $110.40. The stock has a 50 day simple moving average of $104.27 and a 200-day simple moving average of $94.45. The company has a current ratio of 3.02, a quick ratio of 2.44 and a debt-to-equity ratio of 0.14.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.